Need help? Our team of experienced experts is here for you with full support.
AKA-412
AktiAmino™ Fmoc-Lys(Alloc)-OH
Cat. No.
AKA-412
CAS No.
146982-27-6
MF
C25H28N2O6
MW
452.50
AktiAmino™ Fmoc-Lys(Alloc)-OH is a doubly protected L-lysine derivative with an Fmoc-protected α-amino group, an Alloc-protected side-chain ε-amino group, and a free α-carboxyl group. It is used in solid-phase peptide synthesis and selective lysine side-chain modification.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Data
Description
Storage and Shipping
References
Product Name
AktiAmino™ Fmoc-Lys(Alloc)-OH
CAS No.
146982-27-6
MF
C25H28N2O6
MW
452.50
Specification
99%
Documents
Certificate of Analysis (COA), Specification sheet, Safety Data Sheet (SDS/MSDS) etc.
Description
AktiAmino™ Fmoc-Lys(Alloc)-OH is a doubly protected L-lysine derivative with an Fmoc-protected α-amino group, an Alloc-protected side-chain ε-amino group, and a free α-carboxyl group. It is used in solid-phase peptide synthesis and selective lysine side-chain modification. Packing: 1kg/bag,25kg/drum or as request Availability: In stock
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1].Loffet A, Zhang H, inventors. Process for the synthesis of peptides, novel amino acid derivatives used in this process and their preparation methods. European patent application EP0583338A1. 1994 Feb 23.
[2].MedChemExpress. Certificate of analysis: Fmoc-Lys(Alloc)-OH, batch 448696 [Internet]. [cited 2026 Nov 21].
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.